In a pooled analysis of the year-long inTandem1 and 2 trials of the SGLT inhibitor sotagliflozin in T1D, increased DKA incidence was associated with female sex, lower baseline body mass index (BMI), use of continuous subcutaneous insulin infusion (CSII) at baseline, lower insulin requirements at baseline, and insulin dose reductions of ≥10%–20% during the trial.5 Here, INS is linked to type 1 diabetes mellitus.